N,N,N'-trimethylpentanediamine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N,N,N'-trimethylpentanediamine
• 英文别名: N,N',N'-trimethylpentane-1,5-diamine
• 化学式: C₈H₂₀N₂
• 分子量: 144.26
• InChiKey: BRQNTPWYPAHIEQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N,N'-trimethylpentanediamine 在 TBD 作用下， 以 甲苯 为溶剂， 生成 KYS0590
  参考文献：
  名称：

  In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor

  摘要：

  An extension of our previously reported 3.4-dihydroquinazoline derivative is investigated. Oral anti-tumoral activity of 3,4-dihydroquinazoline derivative (KYS05090) as potent and selective T-type calcium channel blocker was in vivo evaluated against A549 xenograft in BALB/c(nu/nu) nude mice. The rate of tumor volume increment in mouse model with KY505090-treated group was remarkably slower than that of control group. With respect to tumor weight, it exhibited 60% and 67% tumor growth inhibition through oral administration of 1 and 5 mg/kg of bodyweight, respectively, compared to control and was more potent than paclitaxel (53%). In addition, KYS05090 (10 and 50 mg/kg, po) was found to have a marked analgesic effect in acetic acid-induced writhing test, whereas it did not show any effect on hot plate test. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.083
• 作为产物：
  描述：

  N,N'-dimethylpentane-1,5-diamine 在 盐酸 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 N,N,N'-trimethylpentanediamine
  参考文献：
  名称：

  In vivo evaluation of oral anti-tumoral effect of 3,4-dihydroquinazoline derivative on solid tumor

  摘要：

  An extension of our previously reported 3.4-dihydroquinazoline derivative is investigated. Oral anti-tumoral activity of 3,4-dihydroquinazoline derivative (KYS05090) as potent and selective T-type calcium channel blocker was in vivo evaluated against A549 xenograft in BALB/c(nu/nu) nude mice. The rate of tumor volume increment in mouse model with KY505090-treated group was remarkably slower than that of control group. With respect to tumor weight, it exhibited 60% and 67% tumor growth inhibition through oral administration of 1 and 5 mg/kg of bodyweight, respectively, compared to control and was more potent than paclitaxel (53%). In addition, KYS05090 (10 and 50 mg/kg, po) was found to have a marked analgesic effect in acetic acid-induced writhing test, whereas it did not show any effect on hot plate test. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.083

文献信息

• 3,4-Dihydroquinazoline derivatives inhibit the activities of cholinesterase enzymes
  作者：Byeongyeon Park、Ji Hye Nam、Jin Han Kim、Hyoung Ja Kim、Valentina Onnis、Gianfranco Balboni、Kyung-Tae Lee、Jeong Ho Park、Marco Catto、Angelo Carotti、Jae Yeol Lee

  DOI：10.1016/j.bmcl.2017.01.068

  日期：2017.3

  respectively. To understand the excellent activity of these compounds, molecular docking simulations were performed to get better insights into the mechanism of binding of 3,4-dihydroquinazoline derivatives. As expected, compound 8b and 8d bind to both catalytic anionic site (CAS) and peripheral site (PS) of BChE with better interaction energy values than AChE, in agreement with our experimental data. Furthermore

  体外测试了一系列3,4-二氢喹唑啉衍生物，这些衍生物由我们的化学文库中选自不同化合物的化合物和新合成的化合物组成，分别测试了它们对乙酰胆碱酯酶（AChE，来自鳗鱼）和丁酰胆碱酯酶（BChE，来自马血清）酶。发现大多数化合物显示出弱的AChE和强的BuChE抑制活性。尤其是，化合物8b和8d是该系列产品中针对BChE的最具活性的IC 50对BChE的亲和力值分别为45 nM和62 nM，以及分别高146和161倍。为了了解这些化合物的出色活性，进行了分子对接模拟，以更好地了解3,4-二氢喹唑啉衍生物的结合机理。如我们所料，化合物8b和8d以比AChE更好的相互作用能值与BChE的催化阴离子位点（CAS）和外围位点（PS）结合。此外，两种化合物的非竞争性/混合型抑制作用在动力学研究中进一步证实了它们的双重结合性质。
• NOVEL COMPOUNDS
  申请人：Blench Toby Jonathan

  公开号：US20130065913A1

  公开（公告）日：2013-03-14

  Compounds of formula (I): are useful as inhibitors of human neutrophil elastase.

  化合物的结构式（I）：作为人类中性粒细胞弹性蛋白酶的抑制剂是有用的。
• [EN] TETRAHYDROTRIAZOLOPYRIMIDINE DERIVATIVES AS HUMAN NEUTROPHIL ELASTASE INHIBITORS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROTRIAZOLOPYRIMIDINE EN TANT QU'INHIBITEURS DE LA NEUTROPHILE ÉLASTASE HUMAINE
  申请人：CHIESI FARMA SPA

  公开号：WO2013037809A1

  公开（公告）日：2013-03-21

  Compounds of formula (I) are inhibitors of human neutrophil elastase.

  化合物的化学式（I）是人类中性粒细胞弹性蛋白酶的抑制剂。
• PROCESS FOR PRODUCING HYDROXYALKYLTRIETHYLENEDIAMINE, AND CATALYST COMPOSITION FOR THE PRODUCTION OF POLYURETHANE RESIN USING IT
  申请人：Tokumoto Katsumi

  公开号：US20110077376A1

  公开（公告）日：2011-03-31

  To provide a process for producing a hydroxyalkyltriethylenediamine or hydroxytriethylenediamine simply and in a small number of steps without requiring multi-stage reaction steps; a novel catalyst composition whereby a polyurethane product can be obtained with good productivity and good moldability without bringing about odor problems or environmental problems; and a process for producing a polyurethane resin using the catalyst composition. For example, a hydroxyalkyltriethylenediamine or hydroxytriethylenediamine is produced by subjecting a mono-substituted dihydroxyalkylpiperazine and/or a di-substituted hydroxyalkylpiperazine to an intramolecular dehydration condensation reaction in the presence of an acid catalyst. Further, for example, a polyurethane resin is produced by using a catalyst composition which comprises a hydroxyalkyltriethylenediamine or hydroxytriethylenediamine (A), and an amine compound (B) having, in its molecule, one or more substituents selected from the group consisting of a hydroxy group, a primary amino group and a secondary amino group, or a tertiary amine compound (C) having a value of [blowing reaction rate constant/gelling reaction rate constant] of at least 0.5.

  提供一种简单且步骤较少的工艺，用于生产羟基烷基三乙烯二胺或羟基三乙烯二胺，而无需进行多级反应步骤；一种新颖的催化剂组合物，可以在不产生异味或环境问题的情况下获得具有良好生产率和良好成型性的聚氨酯产品；以及使用催化剂组合物生产聚氨酯树脂的工艺。例如，通过在酸催化剂存在下，使单取代二羟基烷基哌嗪和/或双取代羟基烷基哌嗪经历分子内脱水缩合反应，可以生产羟基烷基三乙烯二胺或羟基三乙烯二胺。此外，例如，使用催化剂组合物生产聚氨酯树脂，该组合物包括羟基烷基三乙烯二胺或羟基三乙烯二胺（A），以及在其分子中具有一个或多个取代基的胺化合物（B），所述取代基选自羟基、一级胺基和二级胺基的群，或者具有至少0.5的[发泡反应速率常数/凝胶反应速率常数]值的三级胺化合物（C）。
• Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors
  申请人：TAKEDA CHEMICAL INDUSTRIES, LTD.

  公开号：EP0614664A1

  公开（公告）日：1994-09-14

  A composition as which comprise a 1,7-disubstituted-4-oxo-3-quinolinecarboxylic acid or 1,7-disubstituted-4-oxo-3-naphthyridinecarboxylic acid derivative which is useful as a prophylactic and/or therapeutic agent for peripheral arterial obstruction, acute myocardial infarction, an antitumor agent, and as a prophylactic and/or therapeutic agent for osteoporosis.

  一种由 1,7-二取代-4-氧代-3-喹啉羧酸或 1,7-二取代-4-氧代-3-萘啶羧酸衍生物组成的组合物，可用作外周动脉阻塞、急性心肌梗塞的预防和/或治疗剂、抗肿瘤剂以及骨质疏松症的预防和/或治疗剂。